When combined with the ALK inhibitor, EGFR inhibitor gefitinib also showed an anti-cancer effect; however, the pan-HER inhibitor afatinib had a more potent effect on overcoming resistance, indicating the role of HER2 and HER3 activation in resistance. This evidence concerns the gene ERBB3 and cancer.